Purchase of invivoscribe+IGK b-cell clonality assays
Active Purchase Order Awarded Last action
- Contract number
- 75N91026P00014
- Awardee
-
Invivoscribe, Inc. UEI R1EVMK8MEZS9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $57,435
Award facts
- Opportunity
-
- NOI for InvivoScribe IGH+IGK Clonality Mega-ABI Assays Special Notice · 75N91026Q00007 · Posted Feb 12, 2026
- Contract value 100% obligated
- $57,435.00 Current and potential, with all options
- Completion date 62% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute (NCI), a component of the Department of Health and Human Services, awarded a firm fixed-price purchase order valued at $57,435 to Invivoscribe, Inc. on March 5, 2026, for the procurement of InvivoScribe IGH+IGK B-cell clonality assays. This non-competitive sole-source award was issued under the statutory authority of 10 USC 2304(c)(1) and was not subject to any set-aside designation. The assays and associated specimen size control ladder reagents will support the NCI's Molecular Diagnostics Laboratory in performing molecular testing services to identify B-cell clonality and detect B-cell malignancies in cancer patients. Invivoscribe, a San Diego-based manufacturer of precision diagnostics and molecular testing products, was determined to be the only responsible source capable of meeting the laboratory's specific requirements.
The contract has an ultimate completion date of March 4, 2027, and performance will take place in San Diego, California. The NCI has utilized Invivoscribe's IGH/IGK kits since 2009 to maintain the consistency and reproducibility standards required under CLIA and College of American Pathology certification. Invivoscribe has established itself as a key supplier to the NCI through multiple prior purchase orders for specialized biological kits and reagents supporting cancer research initiatives, with this award reflecting the contractor's specialized expertise in molecular diagnostics and the critical nature of these assays to the institute's cancer research operations.
Quick answers
Who was awarded contract 75N91026P00014?
75N91026P00014 was awarded to Invivoscribe, Inc. by National Cancer Institute (National Institutes of Health) on March 5, 2026.
How much is contract 75N91026P00014 worth?
The government has obligated $57,435 on 75N91026P00014.
Was contract 75N91026P00014 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award